Subtopic Deep Dive
P-glycoprotein Mediated Multidrug Resistance
Research Guide
What is P-glycoprotein Mediated Multidrug Resistance?
P-glycoprotein mediated multidrug resistance refers to the overexpression of ABCB1/P-gp transporter in cancer cells that actively efflux chemotherapeutic drugs, reducing intracellular drug accumulation and causing treatment failure.
P-glycoprotein (P-gp), encoded by ABCB1, functions as an ATP-dependent efflux pump expelling diverse substrates including anthracyclines, taxanes, and Vinca alkaloids. Overexpression correlates with poor prognosis in tumors like leukemia and breast cancer. Over 10 papers in the provided list detail its mechanisms, with foundational works exceeding 500 citations each.
Why It Matters
P-gp inhibition restores chemotherapy efficacy in refractory cancers, as shown by Choi (2005) developing chemosensitizers to reverse ABC transporter resistance. In oncology, overcoming P-gp limits tumor relapse post-treatment, per Zahreddine and Borden (2013) who link efflux to clinical resistance. Alfarouk et al. (2015) highlight P-gp's role in ADME failures, impacting 50% of cancer deaths from multidrug resistance.
Key Research Challenges
Substrate Specificity Variability
P-gp recognizes broad substrates but specificity varies across tumors, complicating inhibitor design (Choi, 2005). Polymorphisms in ABCB1 alter transport efficiency, as noted in Löscher and Potschka (2004). This variability hinders universal reversal strategies.
Clinical Translation of Inhibitors
Preclinical P-gp inhibitors fail in trials due to toxicity and poor pharmacokinetics (Alfarouk et al., 2015). Zahreddine and Borden (2013) report low success from off-target effects. Developing safe chemosensitizers remains elusive.
Tumor Heterogeneity in Expression
P-gp levels differ within tumors and stem cells, driving incomplete responses (Bunting, 2002). Tanwar et al. (2014) link heterogeneous expression to emerging resistance crises. Targeting requires precise biomarkers.
Essential Papers
The blood–brain barrier: Structure, regulation and drug delivery
Di Wu, Qi Chen, Xiaojie Chen et al. · 2023 · Signal Transduction and Targeted Therapy · 1.3K citations
Abstract Blood–brain barrier (BBB) is a natural protective membrane that prevents central nervous system (CNS) from toxins and pathogens in blood. However, the presence of BBB complicates the pharm...
Blood-brain barrier active efflux transporters: ATP-binding cassette gene family
Wolfgang Löscher, Heidrun Potschka · 2004 · NeuroRx · 836 citations
Mechanisms and insights into drug resistance in cancer
Hiba Zahreddine, Katherine L. B. Borden · 2013 · Frontiers in Pharmacology · 650 citations
Cancer drug resistance continues to be a major impediment in medical oncology. Clinically, resistance can arise prior to or as a result of cancer therapy. In this review, we discuss different mecha...
Resistance to cancer chemotherapy: failure in drug response from ADME to P-gp
Khalid O. Alfarouk, C C Stock, Sophie Taylor et al. · 2015 · Cancer Cell International · 642 citations
Cancer chemotherapy resistance (MDR) is the innate and/or acquired ability of cancer cells to evade the effects of chemotherapeutics and is one of the most pressing major dilemmas in cancer therapy...
Multidrug Resistance: An Emerging Crisis
Jyoti Tanwar, Shrayanee Das, Zeeshan Fatima et al. · 2014 · Interdisciplinary Perspectives on Infectious Diseases · 640 citations
The resistance among various microbial species (infectious agents) to different antimicrobial drugs has emerged as a cause of public health threat all over the world at a terrifying rate. Due to th...
Polymeric Micelles, a Promising Drug Delivery System to Enhance Bioavailability of Poorly Water-Soluble Drugs
Wei Xu, Peixue Ling, Zhang Tian-min · 2013 · Journal of Drug Delivery · 565 citations
Oral administration is the most commonly used and readily accepted form of drug delivery; however, it is find that many drugs are difficult to attain enough bioavailability when administered via th...
ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal.
Cheol-Hee Choi · 2005 · Cancer Cell International · 504 citations
Reading Guide
Foundational Papers
Start with Löscher and Potschka (2004, 836 citations) for ABC transporter basics in BBB; Choi (2005, 504 citations) for P-gp mechanisms and chemosensitizers; Zahreddine and Borden (2013, 650 citations) for cancer resistance context.
Recent Advances
Emran et al. (2022, 488 citations) on MDR therapeutic approaches; Wu et al. (2023, 1251 citations) for BBB regulation implications.
Core Methods
Efflux assays (radiolabeled substrates), ATPase assays, siRNA knockdown, molecular dynamics simulations, and high-throughput inhibitor screens (Choi, 2005; Alfarouk et al., 2015).
How PapersFlow Helps You Research P-glycoprotein Mediated Multidrug Resistance
Discover & Search
Research Agent uses citationGraph on Choi (2005) to map 500+ citing papers on P-gp chemosensitizers, then findSimilarPapers reveals inhibition strategies in oncology. exaSearch queries 'P-gp ABCB1 cancer efflux inhibitors' across 250M+ OpenAlex papers for substrate lists.
Analyze & Verify
Analysis Agent runs readPaperContent on Löscher and Potschka (2004) to extract BBB-P-gp kinetics, verifies claims with CoVe against Zahreddine and Borden (2013), and uses runPythonAnalysis for dose-response curves from Alfarouk et al. (2015) data via pandas plotting. GRADE grading scores evidence strength for clinical correlations.
Synthesize & Write
Synthesis Agent detects gaps in P-gp inhibitor trials from Emran et al. (2022), flags contradictions between Choi (2005) and recent works, then Writing Agent applies latexEditText for methods sections, latexSyncCitations for 10+ refs, and latexCompile for full review manuscripts. exportMermaid diagrams P-gp efflux pathways.
Use Cases
"Analyze P-gp IC50 data from multiple inhibitor studies"
Research Agent → searchPapers 'P-gp inhibitors IC50' → Analysis Agent → runPythonAnalysis (pandas aggregation, matplotlib boxplots of IC50 distributions by substrate) → researcher gets statistical summary CSV of inhibitor efficacy.
"Write LaTeX review on P-gp reversal strategies"
Synthesis Agent → gap detection across Choi (2005) and Emran (2022) → Writing Agent → latexEditText (draft sections), latexSyncCitations (add 15 refs), latexCompile → researcher gets compiled PDF with figures.
"Find code for P-gp molecular dynamics simulations"
Research Agent → paperExtractUrls from Löscher (2004) → Code Discovery → paperFindGithubRepo → githubRepoInspect → researcher gets annotated GitHub repos with simulation scripts and usage instructions.
Automated Workflows
Deep Research workflow scans 50+ P-gp papers via searchPapers → citationGraph → structured report with GRADE-scored mechanisms from Choi (2005). DeepScan applies 7-step CoVe to verify inhibitor claims in Alfarouk et al. (2015), outputting checkpoint-validated summaries. Theorizer generates hypotheses on P-gp polymorphisms from Löscher and Potschka (2004) data chains.
Frequently Asked Questions
What defines P-glycoprotein mediated multidrug resistance?
P-gp (ABCB1) overexpression in cancer cells effluxes chemotherapeutics via ATP hydrolysis, reducing cytotoxicity (Choi, 2005; Alfarouk et al., 2015).
What are key methods to study P-gp function?
Methods include efflux assays, ATPase activity measurement, and molecular docking for substrates; chemosensitizer screens reverse resistance (Choi, 2005; Zahreddine and Borden, 2013).
What are foundational papers on P-gp resistance?
Löscher and Potschka (2004, 836 citations) on ABC efflux; Choi (2005, 504 citations) on reversal; Zahreddine and Borden (2013, 650 citations) on cancer mechanisms.
What open problems exist in P-gp research?
Challenges include tumor-specific inhibitors without toxicity, heterogeneity in stem cells (Bunting, 2002), and translating preclinical data clinically (Emran et al., 2022).
Research Drug Transport and Resistance Mechanisms with AI
PapersFlow provides specialized AI tools for Medicine researchers. Here are the most relevant for this topic:
Systematic Review
AI-powered evidence synthesis with documented search strategies
AI Literature Review
Automate paper discovery and synthesis across 474M+ papers
Find Disagreement
Discover conflicting findings and counter-evidence
Paper Summarizer
Get structured summaries of any paper in seconds
See how researchers in Health & Medicine use PapersFlow
Field-specific workflows, example queries, and use cases.
Start Researching P-glycoprotein Mediated Multidrug Resistance with AI
Search 474M+ papers, run AI-powered literature reviews, and write with integrated citations — all in one workspace.
See how PapersFlow works for Medicine researchers